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Abstract
Membranous nephropathy (MN) is a very common disease of male adults with nephrotic
syndrome. The disease can be primary, when the cause is not known, or secondary associ-
ated with infections, drugs, neoplasias and autoimmune systemic diseases, such as systemic
lupus erythematosus (SLE). The primary form accounts for 70–80% of the cases. SLE is a
common cause of secondary MN affecting young women. The differential diagnosis from
primary and lupus MN by clinical and morphological findings can be difficult. The search
for autoantibodies against podocyte antigen M-type phospholipase A2 receptor (PLA2R)
has demonstrated high positivity in the serum and renal biopsies in the primary MN and
negativity in lupus MN (WHO class V). There is a large literature on the role of anti-PLA2R
antibody in the diagnosis and follow-up of patients with membranous nephropathy. The
aim of this review is to summarize the literature data on the etiopathogenesis of MN and the
value of anti-PLA2R antibody screening for the diagnosis and management of patients.
Keywords: primary membranous nephropathy, lupus membranous nephropathy,
podocyte antigen M-type anti–phospholipase A2 receptor, podocyte autoantibodies,
differential diagnosis, disease activity
1. Introduction
Membranous nephropathy is a frequent cause of nephrotic syndrome in adults. MN can
manifest as an autoimmune primary disease or can be secondary to a wide variety of condi-
tions such as infections, neoplasias, drugs and autoimmune diseases. The differential diagnosis
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between primary and secondary forms must be made after an extensive clinical and serological
investigation. The clinical course of primary MN is variable, some patients have spontaneous
remission and others show progressive course to chronic renal failure. There is no specific
marker that identifies which patients will develop chronic renal failure. The treatment can be
conservative but sometimes immunosuppressive therapy is required. On the other hand, the
secondary forms ameliorate after the associate condition is removed [1].
Recently, a new autoantigen in the podocyte membrane, an M-type phospholipase A2 receptor
(PLA2R), was discovered in the serum and in the renal biopsies in 70–80% of primary MN
patients. The presence of anti-PLA2R in the glomerular capillary walls by immunohistochemis-
try favors the diagnosis of primary form of MN and excluded the secondary causes. Anti-PLA2R
positive has been very rare in the secondary MN. There are many studies showing anti-PLA2R
negative in the serum and biopsies of membranous lupus nephritis. The serum titers of anti-
PLA2R are usually elevated in the active phase of primary MN and decline in the remission of
disease. In this way, the anti-PLA2R antibody has been used in clinical practice in the differential
diagnosis of primary and secondary forms as well as in the monitoring of disease progression [2].
2. The disease
Membranous nephropathy is a glomerular disease characterized by diffuse and uniform thick-
ening of the glomerular capillary walls caused by the deposition of immune complexes, which
appears by immunofluorescence as granular deposits of IgG and in the ultrastructure as
subepithelial deposits [1] (Figures 1–3).
It is one of the main causes of primary glomerulonephritis worldwide [3, 4]. In the São Paulo
Registry of Glomerulopathies [5] and, in a retrospective epidemiological study conducted in
Brazil with 9617 renal biopsies [6], MN was indicated as the second most prevalent primary
glomerular lesion. In our service, the incidence is 33% [7]. It mainly affects male adults,
between the fourth and fifth decades [8], and is the main glomerulopathy in the elderly [9].
Figure 1. Diffuse thickening of the glomerular capillary walls (HE-200).
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MN presents with high levels of proteinuria of insidious appearance. In 70 to 80% of the cases,
there is nephrotic syndrome with hypoalbuminemia, hypercholesterolemia and edema. Micro-
scopic hematuria is common, and the presence of hypertension varies around 50% of cases.
Renal function is usually preserved; however, chronic renal failure occurs in 40% of cases
within 10 years of evolution. The diagnosis of the disease is made by renal biopsy in the clinical
suspicion of proteinuria or nephrotic syndrome [10–14].
MN can evolve over the years in different ways, from spontaneous remission to persist-
ence of the nephrotic syndrome with a slow and progressive course for chronic renal failure.
Figure 3. Electron-dense epimembranous deposits in the glomerular basement membrane. D = deposit, S = spikes,
GBM = glomerular basement membrane, P = podocyte, and E = endothelial cell (EM-21,000).
Figure 2. Diffuse granular deposits of IgG in the glomerular capillary walls (IF-200).
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Spontaneous remission occurs in about 25–30%. The progression to renal insufficiency is
around 12–18% of the cases [15]. Due to the high rate of spontaneous remission of the disease
and the aggressive specific treatment, it is important to identify prognostic factors that are
associated with progression to renal failure. Among the prognostic factors, age over 50 years,
male gender, presence of arterial hypertension, proteinuria intensity, elevated serum creati-
nine, advanced glomerular stage and presence of interstitial fibrosis in renal biopsy are indica-
tors of disease progression [10–12, 15].
3. The primary or idiopathic form and etiopathogenic aspects
The cause of MN is unknown in 80% of the cases being considered primary or idiopathic [16].
Since the mid-1950s, the understanding of the etiopathogenic mechanisms of MN in experi-
mental models has been sought. The first formulated hypothesis was the deposition of circu-
lating immune complexes in the kidney.
Heymann et al. [17] reproduced in the rat a glomerular lesion similar to that of human MN.
Heymann’s active nephritis was induced by the immunization of rats with rat kidney extracts
in Freund’s adjuvant. The deposits in the glomerular basement membrane were interpreted
as resulting from the passive deposition of circulating immune complexes. Subsequent studies
have shown that glomerular deposits in the subepithelial region were composed of antigens
normally present on the brush border of the proximal tubules and autoantibodies [18]. And in
the Heymann’s passive nephritis, the same disease was reproduced in the rat, using the injection
of the antiserum obtained by immunizing rabbits with brush border proteins of rat kidney [19].
The hypothesis of circulating immune complexes started to be questioned, and a new hypothesis
of local formation of immune deposits by an endogenous antigen localized at subepithelial side
of glomerular basement membrane and a circulating autoantibody was formulated (in situ
immune complexes). Kerjaschki and Farquhar [20] subsequently identified the target autoan-
tigen in the mouse, a protein called megalin, located on the brush border of the proximal tubules
and on the cytoplasmic membrane of the podocyte.
In conclusion, the findings of the experimental studies demonstrated that the podocyte con-
tributes to the formation of immunodeposits in MN, which has been considered an autoim-
mune disease.
Since megalin is not present in human podocytes, the antigen(s) involved in the primary
human MN remains unknown.
In 2002, Debiec et al. [21] identified the first autoantigen in the human MN in a case of neonatal
nephrotic syndrome. The mother with genetic deficiency of neutral endopeptidase (NEP), a
normal protein in the podocytes, was immunized by the fetus with normal expression of NEP.
The anti-NEP antibodies synthesized by the mother were transferred, via the placenta to the
fetus, with formation of in situ immunocomplexes in the kidney. This was a rare familial case of
human neonatal primaryMN by an autoantigen present in the podocyte. However, MN is a very
common pathology, and these findings did not explain all cases of the primary form. Subse-
quently, numerous studies were done in search for other autoantigens responsible for primary
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MN. Beck et al. Salant is the responsible for this Research Group kidney from deceased donors,
not used in transplantation, to extract glomerular proteins that were used in western blot
reaction with circulating antibodies from MN patients. A 185-kD protein was detected in 70%
of patients with primary MN, whereas sera from patients with secondary MN or other glomer-
ular diseases did not react with this protein. The protein was identified by spectrometry as a
transmembrane type M receptor of secretory phospholipase A2 (sPLA2R). The PLA2R super-
family is a heterogeneous group of proteins and enzymes that is present in normal podocytes
and includes the secretory (sPLA2R), cytoplasmic (cPLA2R), and lysosomal (IPLA2R) forms.
They are ubiquitous in nature as an intra- and extracellular form, hydrolyze several phospho-
lipids and act in various biological activities [22, 23]. In the biopsies from patients with idiopathic
MN, the receptor is located next to IgG4, a place consistent with the localization of the immunoc-
omplexes of idiopathic membranous nephropathy [2] (Figure 4).
PLA2R is considered the autoantigen responsible for the development of primary MN in 70–
80% of cases, but there were still 20–30% left without a specific marker. In 2014, a group of
researchers from several countries demonstrated the presence of thrombospondin type 1, with
a 7A domain (THSD7A), another antigenic target in patients with NM that respond for about
10% of the primary cases [24]. More recently, the same group induced MN in animal model
with autoantibodies against THSD7A eluted from renal biopsy of a patient with recurrent MN
in the allograft [25].
There are reports of other podocyte antigens with antigenic and targeting capacity for autoan-
tibody production, but their role is still uncertain and more studies are needed [26].
In conclusion, the findings of NEP, PLA2R, and THSD7A autoantigens in primary MN dem-
onstrated that subepithelial deposits form in situ through the binding of circulating autoanti-
bodies to autoantigens expressed on the surface of podocytes. Heymann’s nephritis was the
basis for understanding the pathogenesis of primary MN.
However, the stimulus that initiates the autoimmune response to podocyte antigens with
disease development is still unknown.
Figure 4. Immunofluorescence staining of PLA2R in glomerular deposits (IF-400).
Antibodies Against M-Type Phospholipase A2 Receptor (PLA2R) in Patients with Primary Membranous Nephropathy…
http://dx.doi.org/10.5772/intechopen.78955
133
There is a strong association between idiopathic MN and HLA-DQA1, located on chromosome
6p21, and the presence of the allele would facilitate the formation of autoantibodies against
PLA2R. In chromosome 2q24, the gene encoding the M-type receptor of phospholipase A2
(PLA2R1) is located [27].
A genetic predisposition can act as a trigger, the dysfunction in the innate immune response
functions as the bullet and the antibody formed against PLA2R the target. As this process
initiate, the disease follows its course. Recently, a publication by Ponticelli and Glassock [28]
has gathered the main information about the pathogenesis of NM: the presence of the HLA-
DQA1 allele predisposes to disease and with PLA2R exposure in the podocyte membrane with
characteristic conformation favors its recognition as autoantigen and starts the process of
autoimmunization. Cells responsible for regulating the innate immune response, such as
dendritic cells, contact with the receptor and presents to CD8+ cells of the adaptive immune
response. Thus, there is a production of IgG4 or IgG1 that binds to the receptor in podocytes
with formation of in situ immunocomplexes. The conformation of the receptor in the cell is
essential to make it more or less antigenic and enable for the formation of autoantibodies.
With the in situ deposition of immunocomplexes, there is activation of the complement system,
lesion of the filtration barrier and loss of proteins to the urinary space. The binding of IgG4 to
PLA2R determines local activation of the complement via mannose, since IgG4 is not able to
activate complement by the classical or alternative pathway, triggering C5 cleavage, and forma-
tion of C5a and C5b. C5a can be eliminated in the urine while C5b binds to other components
until formation of C5b-9. The C5b-9 fraction of the complement (attack complex) activates the
inflammatory response through specific extracellular signaling pathways, with generation of
reactive oxygen species induced by massive biosynthesis of NADPH oxyreductase, lipid perox-
idation, and degradation of the glomerular basement membrane with consequent loss of pro-
teins into the urinary space [29]. There is release of arachidonic acid and eicosanoids with
disruption of the actin cytoskeleton of the podocytes and loss of the diaphragm of the filtration
barrier, leading to detachment of the podocytes from glomerular basement membrane as well as
apoptosis of the podocytes [30]. Persistent proteinuria leads to the intrarenal activation of the
renin-angiotensin system with angiotensin II synthesis, which also promotes proinflammatory
response, activation of transforming growth factor β (TGFβ) and platelet-derived growth factor
(PDGF), recruitment of inflammatory cells, and myofibroblastic activation, which promotes
interstitial fibrosis with concomitant tubular atrophy and chronic renal failure [31].
Studies have been shown that proteinuria, in addition to being directly related to complement
activation, also correlates with the deposits’ characteristics, the degree of podocyte lesion and
CD8+ cellular response [32].
Regarding the pathogenesis of NM, there are doubts in the pathway that change the confor-
mation of PLA2R making it antigenic, the mechanisms of proteinuria, spontaneous remission
and the progression of disease. The understanding of these mechanisms may help to choose
the therapeutic options more efficient and different for each phase of the disease.
In conclusion, the pathogenic mechanism leading to the deposition of immunocomplexes in
the subepithelial region in idiopathic NM is the formation of immunocomplexes in situ. The
expression of phospholipase A2 receptor 1 (PLA2R) on the podocyte membrane is recognized
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as an antigenic stimulus, against which an IgG4 or IgG1 is produced, local complement
activation, inflammatory and oxidative response, with podocyte disruption and lesion in the
filtration barrier with consequent proteinuria.
Ronco and Debiec [33] believe that further studies should be conducted to evaluate whether
PLA2R protein in human MN produces podocyte injury similar to the megalin of Heymann’s
nephritis. The correlation of the anti-PLA2R antibodies with the disease activity and the
presence of the PLA2R protein in the immune deposits suggest that they are the cause and
not consequence of the podocyte injury. On the other hand, the absence of anti-PLA2R anti-
bodies in other pathologies with proteinuria also shows that these antibodies are not only
markers of the disease or of the podocyte lesion [34].
4. The discovery of the PLA2R antigen and the differential diagnosis of the
primary and secondary MN
The secondary form of MN is more rare and is related to infections, autoimmune diseases,
neoplasias and drugs. In children, hepatitis B is a frequent cause of MN and the treatment of
hepatitis with alpha interferon is usually accompanied by remission of proteinuria. Systemic
lupus erythematosus (SLE) often courses with glomerulonephritis, and one type of presenta-
tion is a membranous form (WHO and ISN/RPS class V). About 10% of MN patients are
carriers of neoplasias. The most common sites are gastrointestinal tract, prostate, lung, and
breast. The antigen finding in the biopsies of MN patients, such as HBeAg, HBsAg and HBcAg
in hepatitis B virus, double helix DNA in SLE and carcinoembryonic antigen (CEA) in gastro-
intestinal tract neoplasias, suggests a causal relationship between the underlying disease and
the manifestation of glomerulonephritis. However, the possibility of association of diseases
cannot be ruled out [1].
The investigation of secondary causes with complete clinical examination, serologies and
analysis by images is necessary. After excluding secondary forms, the patients with idiopathic
MN can receive supportive treatment or an immunosuppressive therapy; in the secondary
form, the treatment is directed against the cause of the disease. However, in some patients, MN
may appear months or years before the cause is detected. This makes treatment and clinical
monitoring difficult.
The discovery of the PLA2R antigen brought a number of benefits for the diagnosis and
monitoring of the primary form of the disease. The distinction between the primary and
secondary forms was made easier by the detection of the anti-PLA2R autoantibody in kidney
biopsy and serum of patients, and extensive procedures for differential diagnosis and unnec-
essary exposure to immunosuppression may be excluded.
Several studies have been done with the aim of evaluating the sensitivity and specificity of the
anti-PLA2R autoantibody in renal biopsy and serum of patients with MN.
In a Chinese study of 60 patients with primary and 46 patients with secondary MN, a specific-
ity of 89% [35] was demonstrated. In the Iranian population, anti-PLA2R was detected in 74%
of patients with primary MN and was absent in the secondary form [36].
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5. Relationship between anti-PLA2R antibodies and the disease activity
After the discovery of the PLA2R antigen, studies have sought to establish greater relationships
between the anti-PLA2R antibody and the disease’s immune activity. The association between
antibody titer and disease activity is clear [37]. Two techniques for evaluating anti-PLA2R serum
antibody are described by immunofluorescence or the ELISA method [38–41]. The immunofluo-
rescence test is more sensitive and semiquantitative, while the ELISA test is faster to do and the
values are quantitative, which allows a better evaluation of the evolution of its levels [38].
In a European cohort study, 14 of 18 patients (78%) with primaryMN had anti-PLA2R antibodies
in serum [37]. Segarra-Medrano et al. [42] found a prevalence of anti-PLA2R of 76.6% in patients
with idiopathic MN against 5.8% with secondary MN; the sensitivity of the immunohistochem-
ical reaction in the renal biopsy was 76.6% and the specificity 94.2%. Serum antibody testing
showed similar sensitivity and specificity between Elisa and immunofluorescence reactions
(sensitivity: 72.3  74.4 and specificity: 94.2  94.2, respectively). In another study, Segarra-
Medrano et al. [43] showed a greater reduction in antibody titers in the patients with remission
of disease. In a prospective study, Hoxha et al. [44] showed in 61 of the 88 patients (69%) with
MN a marked deposition to PLA2R with subepithelial location. Of the 61 patients, 98.4% had
antibodies in the serum. This prospective study shows a close correlation between biopsy and
serum positivity; negative reaction in the biopsy is accompanied by the absence of antibodies in
the serum. Performing kidney biopsies and serum tests at different times may result in discrep-
ant results. The serum may be negative in the treatment period, and the biopsy may remain
positive. The analysis of the biopsy is, therefore, important to confirm the diagnosis of primary
MN. Debiec and Ronco [45] also discuss the divergent results between serum and biopsy data;
they demonstrated in 42 patients a serum and biopsies sensitivity of 57 and 74%, respectively. Of
the 42 patients, 21 presented PLA2R positivity in serum and biopsy; in 3 patients, the study was
positive in the serum and negative in the biopsy; in 18 patients, the biopsy was positive and the
serum negative. The presence of PLA2R in the serum in the absence of deposition in the kidney
suggests non-nephritogenic antibody or difficult access to the antigenic epitopes. The fast clear-
ing of serum antibodies or late search in the course of treatment may explain the positivity in the
biopsy with negative serology. Although proteinuria levels are slightly higher in PLA2R-positive
patients [44, 46] and decrease during treatment and disease remission, levels of anti-PLA2R
antibodies usually decrease months before proteinuria, indicating that protein loss in urine is
primarily a result of structural injury of the glomerular basement membrane by inflammation
and not only by the deposition of immunocomplexes.
Svobodova et al. [47] advocate the idea that the analysis of biopsies is very important for the
diagnosis of primary MNmainly in retrospective studies. When serum is not available or there
was clearing of the antibodies in the remission phase of the disease, the biopsy plays a key role
in the diagnosis. When serum samples are collected after a long time of biopsy and during
disease remission, the serum positivity is 22 vs. 59% in the biopsy.
In conclusion, the close relationship between antibody titers in the serum of patients with
idiopathic NM and proteinuria has been recently demonstrated and allows interpreting that
the decline of the antibody predicts remission of the disease. In the study, following the
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initiation of specific immunosuppressive therapy, there was a progressive reduction in circu-
lating antibody levels in the first 3 months, followed by a slow but progressive reduction of
proteinuria levels, which reached their lowest value after about 9 months of onset of follow-up.
Thus, it can be stated that the reduction in the antibody precedes in months the reduction of
proteinuria, and that it is associated with the time to reach remission [46].
Patients with increasing anti-PLA2R antibody titers are less prone to spontaneous remission,
which, together with nephrotic proteinuria, would suggest to use immunosuppression, and
patients with progressive reduction of antibody levels, which could be clinically followed, can
evolve with spontaneous remission [48]. During the follow-up of the patients, the dosage of
the anti-PLA2R antibody brings great contributions. The quantitative and evolutionary evalu-
ation of the antibody can predict spontaneous remission in months, thus avoiding the initia-
tion of specific treatment in patients with greater chances of remission. In cases where there is
an increase in anti-PLA2R antibody levels, there is a greater chance of progression, which
would suggest the initiation of specific treatment, avoiding waiting and decreasing the chance
of disease progression during this period.
The close correlation of the serum levels of the anti-PLA2 R autoantibodies with the immuno-
logical activity of the disease allows the monitoring of the treatment and evaluation of the
prognosis. Patients who present remission of the disease after treatment show a reduction in
antibody titers and proteinuria levels [35, 37, 44, 49] and an increase with relapse [37]. A
prospective study shows that the reduction in anti-PLA2R antibody titers is greater in patients’
remission of the disease. Monitoring of antibody titers after initiation of treatment is useful in
estimating the time to remission of the disease [43]. Beck et al. [49] evaluated the relationship
between levels of the anti-PLA2R antibody and response to Rituximab treatment. Titers
decreased in most patients and anticipated a decrease in proteinuria.
6. Antibodies to M-type phospholipase A2 receptor (PLA2R) and
membranous lupus nephritis
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease affecting
multiple organ systems. The lupus nephritis has many forms of clinical manifestations and
causes the greatest risks of morbidity and mortality. The renal biopsy plays an important role
in the management of patients with SLE. The lupus nephritis classifications, based on renal
pathologic findings, show a wide variety of morphologic expressions, and several classifica-
tions of lupus nephritis have been proposed. A pure membranous form or class V for lupus
nephritis by OMS and ISN/RPS classifications shows similar morphologic findings from idio-
pathic MN and accounts for 8–29% of biopsy series. The presence of C1q by immunofluores-
cence, some degree of mesangial hypercellularity, and small focal subendothelial deposits are
helpful to differentiate from idiopathic MN [50]. Differently from proliferative forms of lupus
nephritis, the patients with a membranous lupus nephritis may present with a normocomple-
mentemic kidney limited disease. The lupus membranous nephritis may precede by years a
clinical diagnosis of SLE and can initially be diagnosed as idiopathic MN [51, 52]. Specific
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serologic markers for membranous lupus nephritis are limited, and a biopsy is required to
discriminate between different forms of lupus nephritis as well as other types of kidney
disorders. Only antibodies to ribosomal P proteins, in the absence of anti–double-stranded
DNA antibodies, have been found to associate with pure membranous lupus nephritis [53].
Although idiopathic membranous nephritis and membranous lupus nephritis have clinical
and histopathologic similarities, the different autoantibody profiles suggest different patho-
genic mechanisms. Many studies confirm the absence of PLA2R antibodies in membranous
lupus nephritis, and its determination is a noninvasive tool to discriminate from idiopathic
MN (Table 1).
7. Conclusions
Membranous nephropathy is one of the main causes of primary glomerulonephritis worldwide.
It mostly affects male adults with nephrotic syndrome. The binding of circulating autoantibodies
to autoantigens expressed on the surface of podocytes forms immunocomplexes in situ and
subepithelial deposits in the glomerular basement membrane. M-type phospholipase A2 recep-
tor on the podocyte membrane is an antigenic stimulus in 70–80% of primary MN and absent in
most of the secondary forms of membranous nephropathy. Studies have shown that PLA2R
antibodies are negative in membranous lupus nephritis, and its determination is a noninvasive
tool to discriminate from idiopathic MN. The discovery of the PLA2 R antigen brought a number
of benefits for the diagnosis and monitoring of the primary form of the disease. The distinction
between the primary and secondary forms was made easier by the detection of the anti-PLA2R
Authors (y) MN-PLA2R (+) Lupus MN-PLA2R (+)
n Biopsy Serum n Biopsy Serum
Beck et al. [2] 37 26 (70%) 26 (70%) 6 0 0
Qin et al. [35] 60 ND 49 (82%) 20 ND 1 (5%)
Hoxha et al. [44] 88 61 (69%) 60 (68%) 5 0 0
Gunnarsson et al. [54] 3 ND 3 (100%) 25 ND 0
Ardalan et al. [36] 23 ND 17 (74%) 1 ND 0
Oh et al. [55] 100 ND 69 (69%) 1 ND 0
Svobodova et al. [47] 65 45 (69%) 26 (40%) 16 0 ND
Segarra-Medrano et al. [42, 43] 47 37 (76%) 4 5 (97%) 8 0 0
Xie et al. [56] — 86/102 (84%) 24/41 (58%) — 1/38(2.6%) 0/13
Dong et al. [57] 179 165 (92%) ND 40 0 ND
Kimura et al. [58] 25 10/19 (52%) 12/25(48%) 13 0 0
ND: not done.
Table 1. Comparisons between PLA2R (+) in primary membranous nephropathy (MN) and lupus membranous
nephropathy (lupus MN).
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autoantibody in kidney biopsy and serum of patients, and extensive procedures for differential
diagnosis and unnecessary exposure to immunosuppression may be excluded. And the serum
titers of anti-PLA2R antibodies are useful to determinate the activity of the disease. In NM, a set
of biomarkers with potential in establishing diagnosis, prognosis and therapeutic guide has
already been identified. The evolution of proteinuria and serum creatinine, coupled with the
evolutionary pattern of the anti-PLA2R antibody, is the best guide for the specific therapeutic
decision in NM.
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